FDA approves Eli Lilly Alzheimer’s drug, expanding treatment options in the U.S.
It's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.
It's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an initial rejection from the FDA last year.
